Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate
about
New and emerging disease modifying therapies for multiple sclerosisM1 and M2 immune activation in Parkinson's Disease: Foe and ally?Current and emerging therapies in multiple sclerosis: a systematic reviewThe CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics.Risks vs benefits of glatiramer acetate: a changing perspective as new therapies emerge for multiple sclerosisOnce-daily glatiramer acetate decreases magnetic resonance imaging disease activity in Japanese patients with relapsing-remitting multiple sclerosis.Drug therapy for multiple sclerosis.Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center studyTwo decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing-remitting multiple sclerosis treatment.Disease-modifying therapies in relapsing-remitting multiple sclerosis.Risk stratification and mitigation multiple sclerosis.Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study.Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.Factors influencing long-term outcomes in relapsing-remitting multiple sclerosis: PRISMS-15.Impact of exposure to interferon beta-1a on outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up studyRestoration of axon conduction and motor deficits by therapeutic treatment with glatiramer acetate.Tracking changes over time in retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in multiple sclerosis.Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis.Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial.Multiple sclerosis review.Vitamin D Status Does Not Affect Disability Progression of Patients with Multiple Sclerosis over Three Year Follow-Up.Longitudinal Evaluation of Visual Function in Multiple Sclerosis.Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala studyExpert recommendations to personalization of medical approaches in treatment of multiple sclerosis: an overview of family planning and pregnancyGlatiramer acetate in treatment of multiple sclerosis: a toolbox of random co-polymers for targeting inflammatory mechanisms of both the innate and adaptive immune system?Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b studyCurrent and future immunomodulation strategies to restore tolerance in autoimmune diseases.Interferon beta and glatiramer acetate therapy.An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis.Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus studyNeuropathic pain in animal models of nervous system autoimmune diseases.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Mortality in patients with multiple sclerosisTranslational research in neurology and neuroscience 2010: multiple sclerosisImmunomodulatory drug treatment in multiple sclerosis.Drug delivery technologies for autoimmune disease.Fingolimod for the treatment of relapsing multiple sclerosis.
P2860
Q22242305-45014E62-D898-4BA9-A8F1-BC72C99D3B07Q27024667-6AE31ED2-1850-4C9F-84ED-F055F5E2D3E4Q29010983-7B4528AE-5DD0-4894-A6BB-BF8BC9C194C2Q30932853-8DDC3DB1-59E5-4C93-B474-2CFF528FEF7EQ33802186-4FA2087F-52FF-42ED-874A-B2AEBE26F365Q33835877-1DFC81AB-DDA2-40EC-A028-9A988AADDC1BQ33990246-3B39BE84-F886-4065-9AA4-7377DE7BEC48Q33990861-3AFC460F-860D-4D2E-8F04-CBC71779EAAAQ34090086-A90E97C3-8B52-4B2A-8E3A-0638E212154CQ34122924-8F03AB71-6DCF-4D91-B4D2-ECA1B94D059DQ34155446-BAB13869-5193-44D5-8862-5FA0A7C59E8CQ34293871-A77EBFF1-72FB-4B96-91F8-11FC5CB5A28BQ34473419-FD3A3B29-43E7-443E-941D-B40F05EEA0C0Q34494321-E57DF655-83E2-4752-A479-1F6BC43648F4Q34565669-F342488D-318F-44EC-8562-A4C6D1CC3C81Q35008641-4081B271-4335-41BE-8B24-4F59575359EAQ35013317-B0942B39-3A1D-4C86-AC30-323405AB6EEFQ35276622-60EBCBF9-3B8D-4FCB-8123-AC0783D39F48Q35374052-F89955D2-972B-46D0-B774-5708458D05E8Q35446549-942184C6-C626-42D9-9B25-F58F58700DE4Q35909839-7563ABDD-8303-459E-BCF3-CD0559B4A97FQ35958691-24FFF798-458D-4434-93E7-317592FE6695Q36045080-82DB6A98-B956-4DB4-8E4F-7675DAF68E4EQ36090219-3288C13B-9369-4968-A95A-F34C3964C647Q36136472-E12EC74F-B9F9-43CA-BD78-1961EDBBCA1BQ36171531-9BB3501A-679A-49A7-9D57-697E7BFFA77AQ36298897-ECB398EA-FB54-4A69-A276-295EB6F50F06Q36432500-43A08E8E-A4E6-468E-9A41-0176FE792087Q36496516-860DAD9E-BE6C-429A-888A-42BFC6FAA679Q36506677-B9398CED-E462-4986-B099-5D9CFC2B77CBQ36568660-2B3E1B62-9547-4EDB-A6EC-AC4850FF3FB6Q36670128-1F2EF3AB-3D28-4DFB-83C9-2BA720F090E5Q36731484-CF8AFB62-9CB3-4CEA-B742-131D41AE7722Q36869524-982F2E90-16D3-424D-973E-439D597D896EQ36975701-44F16A99-0CE7-49DB-927D-94517250516CQ37163309-12A1D375-CB03-4712-8D2C-C16102963EC3Q37772026-01BDA915-5E63-466A-BA57-5AC7F5072F58Q37785554-F0332119-E325-4529-86FE-C33B9C134FFDQ37801381-D42167DF-554B-4355-B2F5-F5562D57B266Q37821010-6CF6EB59-8B65-4809-BE4E-3E33BBC489CB
P2860
Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Continuous long-term immunomod ...... el study of glatiramer acetate
@ast
Continuous long-term immunomod ...... el study of glatiramer acetate
@en
Continuous long-term immunomod ...... el study of glatiramer acetate
@nl
type
label
Continuous long-term immunomod ...... el study of glatiramer acetate
@ast
Continuous long-term immunomod ...... el study of glatiramer acetate
@en
Continuous long-term immunomod ...... el study of glatiramer acetate
@nl
prefLabel
Continuous long-term immunomod ...... el study of glatiramer acetate
@ast
Continuous long-term immunomod ...... el study of glatiramer acetate
@en
Continuous long-term immunomod ...... el study of glatiramer acetate
@nl
P2093
P2860
P3181
P356
P1476
Continuous long-term immunomod ...... el study of glatiramer acetate
@en
P2093
A D Goodman
J Preiningerova
J W Lindsey
J Wolinsky
P2860
P304
P3181
P356
10.1177/1352458509358088
P407
P577
2010-03-01T00:00:00Z